Cargando…

MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2

Prostate cancer (PCa) is widespread cancer with significant morbidity and mortality rates. MicroRNAs (miRNAs) have been identified as important post-transcriptional modulators in various malignancies. This study investigated the miR-124-3p effect on PCa cell proliferation, infiltration, and apoptosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Bao-feng, Xu, Li-zhe, Jiang, Kun, Cheng, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995421/
https://www.ncbi.nlm.nih.gov/pubmed/36884182
http://dx.doi.org/10.1007/s10142-023-00991-8
_version_ 1784902820270440448
author Song, Bao-feng
Xu, Li-zhe
Jiang, Kun
Cheng, Fan
author_facet Song, Bao-feng
Xu, Li-zhe
Jiang, Kun
Cheng, Fan
author_sort Song, Bao-feng
collection PubMed
description Prostate cancer (PCa) is widespread cancer with significant morbidity and mortality rates. MicroRNAs (miRNAs) have been identified as important post-transcriptional modulators in various malignancies. This study investigated the miR-124-3p effect on PCa cell proliferation, infiltration, and apoptosis. EZH2 and miR-124-3p expression levels were measured in PCa tissues. PCa cell lines DU145 and PC3 were transfected with miR-124-3p inhibitors or analogs. EZH2 and miR-124-3p linkage was validated by conducting the luciferase enzyme reporter test. The cell viability and apoptosis were assessed by flow cytometry and MTT test. Cell movement was noted during infiltration using transwell assays. EZH2, AKT, and mTOR contents were assessed using qRT-PCR and western blotting. In clinical PCa specimens, miR-124-3p and EZH2 contents were inversely correlated. Further research has demonstrated that EZH2 is the miR-124-3p direct target. Furthermore, miR-124-3p overexpression reduced EZH2 levels and lowered cell viability, infiltration, and promoted cell death, whereas miR-124-3p silencing had the opposite effect. Overexpression of miR-124-3p decreased the phosphorylation level of AKT and mTOR, whereas miR-124-3p downregulation produced the opposite result. Our findings depict that miR-124-3p prevents PCa proliferative and invasive processes while promoting apoptosis by targeting EZH2.
format Online
Article
Text
id pubmed-9995421
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-99954212023-03-10 MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2 Song, Bao-feng Xu, Li-zhe Jiang, Kun Cheng, Fan Funct Integr Genomics Original Article Prostate cancer (PCa) is widespread cancer with significant morbidity and mortality rates. MicroRNAs (miRNAs) have been identified as important post-transcriptional modulators in various malignancies. This study investigated the miR-124-3p effect on PCa cell proliferation, infiltration, and apoptosis. EZH2 and miR-124-3p expression levels were measured in PCa tissues. PCa cell lines DU145 and PC3 were transfected with miR-124-3p inhibitors or analogs. EZH2 and miR-124-3p linkage was validated by conducting the luciferase enzyme reporter test. The cell viability and apoptosis were assessed by flow cytometry and MTT test. Cell movement was noted during infiltration using transwell assays. EZH2, AKT, and mTOR contents were assessed using qRT-PCR and western blotting. In clinical PCa specimens, miR-124-3p and EZH2 contents were inversely correlated. Further research has demonstrated that EZH2 is the miR-124-3p direct target. Furthermore, miR-124-3p overexpression reduced EZH2 levels and lowered cell viability, infiltration, and promoted cell death, whereas miR-124-3p silencing had the opposite effect. Overexpression of miR-124-3p decreased the phosphorylation level of AKT and mTOR, whereas miR-124-3p downregulation produced the opposite result. Our findings depict that miR-124-3p prevents PCa proliferative and invasive processes while promoting apoptosis by targeting EZH2. Springer Berlin Heidelberg 2023-03-08 2023 /pmc/articles/PMC9995421/ /pubmed/36884182 http://dx.doi.org/10.1007/s10142-023-00991-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Song, Bao-feng
Xu, Li-zhe
Jiang, Kun
Cheng, Fan
MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2
title MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2
title_full MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2
title_fullStr MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2
title_full_unstemmed MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2
title_short MiR-124-3p inhibits tumor progression in prostate cancer by targeting EZH2
title_sort mir-124-3p inhibits tumor progression in prostate cancer by targeting ezh2
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995421/
https://www.ncbi.nlm.nih.gov/pubmed/36884182
http://dx.doi.org/10.1007/s10142-023-00991-8
work_keys_str_mv AT songbaofeng mir1243pinhibitstumorprogressioninprostatecancerbytargetingezh2
AT xulizhe mir1243pinhibitstumorprogressioninprostatecancerbytargetingezh2
AT jiangkun mir1243pinhibitstumorprogressioninprostatecancerbytargetingezh2
AT chengfan mir1243pinhibitstumorprogressioninprostatecancerbytargetingezh2